Roxana Mustafa Edme, Georgică TÃrtea, Ionuț Donoiu, Gianina Moise, Cristina Florescu
Department of Internal Medicine-Cardiology, Craiova University of Medicine and Pharmacy, Craiova 200349, Romania.
Department of Physiology, Craiova University of Medicine and Pharmacy, Craiova 200349, Romania.
Curr Cardiol Rev. 2019;15(4):283-290. doi: 10.2174/1573403X15666190326150550.
Natriuretic peptides, produced by cardiac myocytes, are regulators of the intravascular volume and blood pressure, and also exhibit neuroendocrine, metabolic and growth controlling effects. In heart failure, their synthesis increases exponentially as part of the neuroendocrine activation, but their beneficial effects are diminished. The paper reviews relevant data about their role as diagnosis and prognosis markers in heart failure, the hemodynamic and clinical benefits of their use as therapy in heart failure, together with the main adverse effects. Peptides non-specifically increase in extracardiac pathology and the literature reveals the mechanisms of increase, significance and threshold values to exclude cardiac dysfunction.
利钠肽由心肌细胞产生,是血管内容量和血压的调节因子,还具有神经内分泌、代谢和生长控制作用。在心力衰竭中,作为神经内分泌激活的一部分,它们的合成呈指数级增加,但其有益作用却减弱。本文综述了有关它们作为心力衰竭诊断和预后标志物的作用、作为心力衰竭治疗手段的血流动力学和临床益处以及主要不良反应的相关数据。肽类在心脏外病变中会非特异性增加,文献揭示了其增加的机制、意义以及排除心脏功能障碍的阈值。